Reimagine Vitiligo
Treatment with Lumirix®
Lumirix® is the first topical treatment approved for vitiligo.1
This image is for illustrative purposes only.
Discover the Clinical Evidence and Therapeutic Considerations in Vitiligo Management
Efficacy Profile
Lumirix® is supported by clinical studies that show significant improvements in skin repigmentation.²
Mechanism of Action
Lumirix® works by targeting the underlying mechanisms of vitiligo, providing a focused treatment approach.³
Safety Profile
Lumirix® has demonstrated a favorable safety profile in clinical trials with manageable side effects.²,⁴
Resources for Doctors
Get comprehensive patient support and resources to help you throughout your treatment journey.
References
- Grossmann MC, Haidari W, Feldman SR. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo. Journal of drugs in dermatology: JDD. 2023;22
- Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D. Two phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo. New England Journal of Medicine. 2022 Oct 20;387(16):1445-55.
- Lumirix® Prescribing information for Hong Kong.
- Huang H, et al. Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo. J Am Acad Dermatol 2025;93(2):475–477.
